Skip to Content

Atripla Approval History

  • FDA approved: Yes (First approved July 12th, 2006)
  • Brand name: Atripla
  • Generic name: efavirenz, emtricitabine and tenofovir disoproxil fumarate
  • Dosage form: Tablets
  • Company: Bristol-Myers Squibb Company / Gilead Sciences, Inc.
  • Treatment for: HIV Infection

Atripla is a once-daily single tablet regimen combining the non-nucleoside reverse transcriptase inhibitor Sustiva (efavirenz), and the nucleoside reverse transcriptase inhibitors Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate). Atripla is indicated as a stand-alone therapy or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults.

Development History and FDA Approval Process for Atripla

Jan 11, 2010Approval HIV/AIDS Update - Atripla label update reflects new efficacy, safety and resistance data in treatment experienced patients
Jul 12, 2006Approval Atripla Bristol-Myers Squibb Company / Gilead Sciences, Inc. - Treatment for HIV-1 Infection

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.